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Abstract: Men undergo gradual bone loss with aging, resulting in fragile bones. It is estimated 
that one in five men will suffer an osteoporotic fracture during their lifetime. The prognosis for 
men after a hip fracture is very grim. A major cause is reduction of free testosterone. Many other 
factors result in secondary osteoporosis, including treatment for other diseases such as cancer 
and diabetes. Patients should be screened not only for bone density but also assessed for their 
nutritional status, physical activity, and drug intake. Therapy should be chosen based on the 
type of osteoporosis. Available therapies include testosterone replacement, bisphosphonates, 
and nutritional supplementation with calcium, vitamin D, fatty acids, and isoflavones, as well as 
certain specific antibodies, like denosumab and odanacatib, and inhibitors of certain proteins.
Keywords: risk factors, hormones, bisphosphonates, nutritional supplements, antibodies, 
protein inhibitors, male osteoporosis
Introduction
Aging is associated with gradual bone loss in men, leading to fragile bones and 
increased fracture risk. Since bone loss in males was recognized as a serious medi-
cal condition a couple of decades ago, studies have focused on several aspects of 
the disease, including assessment, diagnosis, prevention, and treatment options. It is 
established that aging men lose bone mineral density (BMD) at a rate of 1% per year,1 
and that one in five men will suffer an osteoporotic fracture during their lifetime.2,3 
It is also believed that the incidence of osteoporosis-related fracture is similar to that 
of myocardial infarction and exceeds that of lung and prostate carcinoma combined.4 
The disturbing fact is that when men have fractures, their chances of survival are 
considerably decreased. Moreover, awareness about osteoporosis in males is lacking 
in certain societies.5–7
Although it is recognized that osteoporosis in men is an important medical 
condition and will remain important as longevity increases around the globe, there 
are very poor tools for managing male osteoporosis.8,9 The diagnostic standards are 
dependent on the scales for women or young men, but there is a 10-year difference 
in age before men show signs of an age-related decrease in bone mass.10 Moreover, 
many elderly men treated for fractures are not put on any medication regimen to treat 
osteoporosis.11 It is recommended that men should be evaluated for their bone status 
after 50 years of age,12 and the clinical practice guidelines recommend screening in 
men over 70 years.11,13
Patients older than 80 years are currently excluded, but the changes in physiology 
at this age usually put them at a different level of risk.14 Although screening patients 
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for BMD is the best measure to know the status of bone, it 
is very important to collect information about the probable 
reasons for bone loss, because 75% of patients have been 
found to have secondary osteoporosis.15 There may be 
ethnicity-related differences among men as well. Roughly 
7% of white men and 3% of black men have osteoporosis, 
with an additional 35% of white men and 19% of black men 
having low bone mass. This requires formulation of treatment 
and management strategies specific to ethnic groups.16 In 
addition to this, men with a combination of low bone mass 
and low muscle mass are at higher risk of losing bone. In 
this review, available data on the causes, consequences, and 
treatment options are discussed.
Causes and consequences
Several factors are believed to cause age-related bone loss 
in men, including decreased levels of sex hormones and 
insulin-like growth factor-1, drug side effects, and nutrition 
lacking minerals. Moreover, secondary osteoporosis may 
be due to several acquired habits and inherited conditions 
(Figure 1).
Decrease in hormones
With age, there is certainly a decrease in hormone levels. 
Androgens may play an important role in the regulation of 
bone formation in men.17 Total testosterone levels decrease at 
a rate of 0.8% per year, of which free and bound testosterone 
levels decrease at 2% per year (cross-sectional studies) and 
between 1.6% per year and 2%–3% per year (longitudinal 
studies).18 On the other hand, levels of sex hormone bind-
ing globulin (SHBG) increase with age.19–23 This protein 
binds to testosterone and decreases free or bioavailable 
testosterone.19,21,24–26 Men are also affected by changes in 
estrogen due to aging, because testosterone is the precursor to 
estrogen and it is well established that estrogen plays a greater 
role in increasing bone resorption.25 Therefore, in men, both 
hormones are important to maintain bone and are inversely 
related to fracture risk in older men contributed by decreased 
BMD.27,28 The action of androgen on bones in males may be 
explained by activation of the androgen receptor or the estro-
gen receptor (α and β).28 Therefore, low serum estrogen and 
testosterone with high SHBG increases the risk of osteoporotic 
vertebral, nonvertebral, and hip fractures.28,29
Figure 1 Factors that cause bone loss in men. 
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Apart from alterations in sex hormones, decreased 
insulin-like growth factor-1 levels are found in men with 
vertebral fractures.30 In addition, men with a low body mass 
index and a small body frame have decreased estrogen levels, 
and the offspring of these men also have low BMD.31
Bone turnover and bone maintenance is a balance between 
proteins like osteoprotegerin and receptor activated nuclear 
factor kappa B ligand (RANKL). Osteoprotegerin levels in 
serum have been shown to increase with age,32 which in turn 
may increase bone loss.
Side effects of drugs
Patients with prostate cancer undergoing androgen depri-
vation and cyclophosphamide therapy have an increased 
fracture risk.33–36 BMD measurements in men with prostate 
cancer and under an androgen deprivation regimen show 
6.5%–17.3% bone loss. Moreover, this effect is site-specific 
and is also dependent on duration of treatment.37–39
Antidiabetic drugs like thiazides also cause bone loss.40 
Many studies in humans as well as in animals have shown 
that bone loss is accelerated by thiazoles.41–43 Rosiglitazone 
decreases bone quality by increasing porosity.40 In women 
and men, decreased bone mass in long bones, but not in 
the vertebrae, has been attributed to thiazides.44,45 There are 
a few studies that explain the mechanism by which these 
antidiabetic drugs cause bone loss. In males, glitazones 
reduce the biosynthesis of androgens, increase their binding 
to SHBG, and attenuate androgen receptor activation, thus 
reducing the physiologic actions of testosterone, causing 
relative and absolute androgen deficiency.46 In addition to 
this, activation of peroxisome proliferator activated receptor 
gamma initiates an imbalance in the bone resorption and bone 
formation process, resulting in high bone loss.47 Moreover, 
rosiglitazone induces apoptosis of osteoblasts which reduces 
bone formation.48
Changes in bone turnover markers
Bone turnover is assessed by measuring biomarkers such 
as cross linking C-terminal telopeptide of type I collagen 
and procollagen type 1 N-terminal propeptide. Cross link-
ing C-terminal telopeptide of type I collagen, in addition 
to being a bone resorption marker, is also used to assess 
adherence with bisphosphonates, while procollagen type 
1 N-terminal propeptide is a measure of bone formation. 
Higher bone turnover is not always related to decreased 
BMD in men.49 However, in the Dubbo study, only cross link-
ing C-terminal telopeptide of type I collagen could predict 
fractures.50 Increased bone turnover reduces bone strength 
because faster bone loss increases bone formation. This 
sudden increase in bone formation impairs bone connectivity 
because a higher fraction of protein matrix undergoes partial 
post transcriptional modification, resulting in a malformed 
matrix. It is commonly observed that bone turnover mark-
ers are increased in institutionalized patients51 to a greater 
extent than in community-dwelling individuals. In older 
men, increased bone turnover markers are associated with 
lower areal BMD.49
Secondary osteoporosis
Most men who sustain fractures do so because of multiple 
other factors, including age, smoking, alcohol consump-
tion, low weight, physical/functional limitations, previous 
fracture, weight loss, prolonged corticosteroid use, androgen 
deprivation therapy, dietary calcium intake, chronic lung dis-
ease, and prostate cancer. Accumulation of kidney stones is 
negatively correlated with BMD.52–54 Recent research shows 
that low levels of free 25(OH) vitamin D result in bone loss.55 
The major mineral lost in bone loss is calcium, and calcium 
absorption is influenced by vitamin D.  Therefore, individuals 
who consume calcium in low amounts and who are diagnosed 
with vitamin D deficiency also have an increased fracture 
risk.56–58
Osteoporosis affects men over 70 years of age. When 
BMD in both the trabecular and cortical bones is reduced, 
there is an increased risk of fractures of the hip and vertebrae, 
which are often fatal in men. Some patients have hypogonad-
ism due to testicular failure or pituitary disorders, leading 
to bone loss.59 Medications for other medical conditions, 
including those for cancer, diabetes, and seizures, also cause 
osteoporosis.60 Apart from these, drugs that raise serum 
prolactin levels and chronic opioid use for pain control are 
also implicated in bone loss. Men who have fractures of the 
distal forearm and those who have symptomatic vertebral 
and hip fractures show lower BMD as well.61
Nevertheless, men have the advantage of accruing a higher 
peak bone mass (8%–10%) compared with women.62,63 In 
addition, microarchitectural changes in the radius have been 
found to include higher trabecular thickness and bone volume/
total volume in men compared with women.64,65 In the tibia, 
significantly higher bone volume/total volume, trabecular 
number, and cortical thickness65 were reported. Although tra-
becular thickness was also increased, this was not statistically 
significant. However, these data are from younger individuals 
aged 19 years and 20–29 years.  Longitudinal studies in older 
men showed an age-related decrease in trabecular thickness of 
the radius. However, there was decreased trabecular thickness, 
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number, and separation in the distal tibia.66 Cortical porosity is 
increased with age in men.67 Moreover, men undergo periosteal 
bone accretion compensating the endosteal bone loss and 
maintaining strength for almost a decade after women show 
bone fragility.66–70 However, men do lose bone gradually and 
are susceptible to fractures after the sixth decade of life.
The action of androgen on male bone may be explained 
by activation of the androgen receptor or estrogen receptor 
(α and β).28 Serum estrogen and testosterone are inversely 
related to fracture risk in older men, while SHBG shows a 
positive relationship; low serum estrogen and testosterone 
levels coupled with high SHBG predict clinical vertebral 
and nonvertebral osteoporosis and hip fractures.17 SHBG 
has been reported to increase with age and is associated 
with bone loss.29
Orchidectomized rodents have been shown to have an 
increase in bone resorption markers and periosteal bone for-
mation, and decreased bone strength, implicating the role of 
decreased testosterone.71 Because androgens play an important 
role in regulation of bone formation in males, their receptors, 
ie, the androgen receptor and estrogen receptor, should be 
activated for maintenance of bone in male mice. Estrogen 
receptor-α and the androgen receptor were found to increase 
cortical radial bone growth and mediate protection of cancel-
lous bone in males.71 Moreover, androgen receptor activation 
is solely responsible for the development and maintenance 
of trabecular bone in males, and the androgen receptor and 
estrogen receptor-α are responsible for cortical bone mass 
and muscle mass.72,73 It is reported that estrogen receptor-α 
may act indirectly via the growth hormone-insulin-like growth 
factor-1 axis.74 Therefore, there is ample evidence that an 
age-related reduction of hormone secretion, especially sex 
hormones, affects bone maintenance in men.
Osteoporosis in men is a gradual disease that progresses 
with age.14 In the US, two million men are diagnosed with 
osteoporosis and another 12 million have low bone mass and 
are at the risk of developing the disease.75 The outcome for 
male patients after hip fracture (30% of hip fractures occur 
in men) is grim. One third (32%) die within the first year of 
hip fracture.76–78 Only 21% are able to live independently in 
the community a year after the fracture, with 26% receiv-
ing home care and 53% living in an institution for the rest 
of their lives.79 Unfortunately, men with osteoporosis have 
higher mortality rates than women, and the fracture burden 
also increases the problems of osteoporosis in men. In one 
study, men with subsequent fractures were found to have an 
increased mortality rate and more men were immobilized at 
120 days after their fracture.11
Treatment options
Available treatment options for men with osteoporosis are 
those that were developed for and are currently used in 
women. Many of these drugs/supplements have been very 
beneficial in males as well, and include hormones, bispho-
sphonates, antibodies, protein inhibitors, and nutritional 
supplements (Figure 2). Pharmacologic options for treating 
osteoporosis in men are listed in Table 1.
Hormones
Hormone therapy, especially estrogen, has been widely used 
to treat osteoporosis in women. Testosterone supplementa-
tion is also used in men, because a decrease in testosterone 
is linked to decreased bone mass. With such therapy, site-
specific improvement has been reported in some cases, with 
benefits only at the spine and not at the hip.80,81 Moreover, 
treatment with testosterone not only increased BMD82 but 
also increased prostate gland size and prostate specific anti-
gen (PSA) levels. However, the prostate size is not affected 
when testosterone was given with finasteride (inhibitor 
of 5alpha reductase), therefore in these patients androgen 
replacement therapy was effective.52 It is important to note 
that testosterone treatment should be given only to those 
who have low levels of testosterone and need agents that will 
prevent fractures.80,83
The only anabolic bone agent approved by the US Food and 
Drug Administration for prevention and treatment of osteopo-
rosis is teriparatide, a truncated parathyroid hormone. It may 
be one option for treating osteoporosis in men because it is 
associated with major gains in BMD at the lumbar spine, but 
less at the hip.4,14,80,84–86 Bone formation markers also increased 
with this treatment, and the risk of fracture reduced by 51%.87 
In patients with existing vertebral fractures, the risk went down 
to 13:1. However, continuous treatment with teriparatide is not 
recommended because of several side effects. Combination 
therapy using bisphosphonates and teriparatide did not increase 
BMD, however, patients on teriparatide therapy alone showed 
significantly increased BMD, in the lumbar and femur neck, 
although the BMT were similar in both groups (combined 
and teriparatide groups).88 At this point in time, the Food and 
Drug Administration has approved the use of teriparatide only 
for 24 months. After cessation of teriparatide, patients show a 
gradual decrease in BMD unless they are put on other medi-
cations.87 Although combination treatment with alendronate 
was not encouraging, administration of alendronate after teri-
paratide treatment maintained BMD, so sequential treatment 
is recommended.86,89,90 Whenever treatment with teriparatide 
was restarted, there was an increase in BMD.91
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Table 1 Pharmacological options available for treating osteoporosis in men
Drug Dosage/Frequency Advantages Side effects References
Hormones
Testosterone  Hypogonadal men,  
BMD at lumbar vertebrae
Fluid retention, increased  
blood pressure
59,81,84
 intramuscular 200 mg/every 2 weeks
 Skin patch 5 mg daily
 Gel 50 mg/5 g daily
Parathyroid hormone  BMD, bone formation 
markers
Dizziness, nausea, palpitations, 
hypercalcemia
85–88
Calcitonin  BMD of lumbar and  
femoral neck
Dizziness, nausea, pain 92,93,109
Selective estrogen receptor modulator
Raloxifene  Bone mass 94,95
Bisphosphonates
Alendronate 10 mg daily or 70 mg weekly  BMD in vertebrae,  
femoral neck
Gi tract intolerance 88,91
Risendronate 5 mg daily or 35 mg weekly or  
75 mg monthly (2 consecutive  
days) or 150 mg monthly
 Bone mass Gi tract intolerance 14
Etidronate 400 mg daily  BMD in lumbar  
vertebrae
Gi tract intolerance, joint, bone,  
and muscle pain, severe diarrhea,  
jaw pain, numbness or swelling,  
hives, swelling of mouth and throat
98
ibandronate 2.5 mg daily or 150 mg  
monthly or 3 mg every  
3 months (iv)
 BMD spine,  
trochanter, femur neck
GI tract intolerance, flu-like  
symptoms, osteonecrosis of jaw
99,102
Zoledronate 5 mg yearly (iv)  Bone mass Flu-like symptoms,  
osteonecrosis of jaw
101,103,104,118
Abbreviations: iv, intravenously; Gi, gastrointestinal; BMD. bone mineral density; , increase.
Figure 2 Treatment options for osteoporosis in men. 
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Another hormone that regulates circulating calcium 
is calcitonin. This hormone is a powerful inhibitor of 
osteoclasts. Administration of this agent is nasal, and it is 
reported to increase BMD at the lumbar spine and femoral 
neck but not at the proximal femur.4,14,82,86,92,93 During the 
last decade, calcitonin has been tested as a treatment option 
for osteoporosis in men.92,93 Growth hormone would also be 
beneficial to patients who are growth hormone-deficient.
Administration of hormones like testosterone, parathyroid 
hormone, and calcitonin may be useful for preventing bone 
loss and increasing bone mass. However, such treatment 
options should be used on an individual basis. Outcomes are 
dependent on the initial hormone status in some cases, while 
sequential treatment may be important in others.
Selective estrogen receptor modulators
Selective estrogen receptor modulators bind to estrogen 
receptors and have estrogen-like activity in bone. Raloxifene 
has been shown to increase bone mass and decrease urinary 
and circulating bone resorption markers.94,95 However, use of 
these agents may be limited to men with prostate cancer.
Bisphosphonates
Bisphosphonates are recommended for treating osteoporosis 
in men.4,80,86 Alendronate (Fosamax®, Merck, Whitehouse Sta-
tion, NJ, USA) improves BMD at the vertebrae and femoral 
neck in both eugonadal and hypogonadal men, with signifi-
cant reductions in the incidence of vertebral fractures and less 
height loss.14,82,96,97 Other bisphosphonates like risendronate 
(Actonel®, Warner Chilcott, Dublin, Ireland) and ibandronate 
(Boniva®, Genentech Inc, South San Francisco, CA, USA) 
are also options for treating osteoporosis in men.14 Intermit-
tent etidronate (Didronel®, Warner Chilcott, Dublin, Ireland) 
therapy increases BMD at the lumbar spine by 3%, with 
smaller increases at the hip (0.7%) in patients with second-
ary osteoporosis.82,98 Ibandronate, another bisphosphonate, 
when given intravenously in combination with calcium and 
vitamin D supplementation increased BMD at the spine, 
femoral neck, and trochanter in a small study of 14 indi-
viduals.99 In yet another study, administration of ibandronate 
increased BMD at the lumbar vertebrae and hip in men 
and significantly reduced the risk of vertebral fractures.100 
Zoledronate (Zometa®, Zomera®, Aclasta®, Reclast®, Novar-
tis, Basel, Switzerland) may be an alternative (administered 
intravenously, which may be better than the oral route for 
bisphosphonates) and is shown to be as effective as other 
bisphosphonates.14,101–104 Bisphosphonates have been shown 
to be effective therapeutic agents for patients with osteopo-
rosis, but there are certain limitations in using them. Many 
patients show tolerance, and each of the oral bisphosphonates 
has very strict and specific guidelines for dosage. However, 
great strides have been made in developing drugs that can 
be taken daily, weekly, monthly, or even yearly.
Antibodies and protein inhibitors
A recent trend in drug development has focused on tar-
geting important proteins involved in development of 
osteoporosis. Specific antibodies and inhibitors of these 
proteins have been developed, and are listed in Table 2. 
RANKL stimulates osteoclastogenesis and increases bone 
resorption. Denosumab, a monoclonal antibody against 
RANKL, is one of the newer medications that is available 
as a therapeutic option.14,94,105,106 It decreases bone resorp-
tion, thereby decreasing bone loss. This antibody should be 
taken with caution because it can affect the immune system, 
leading to infections.
Another protein, cathepsin K, which is expressed in osteo-
clasts and is capable of releasing minerals from bone, has 
Table 2 Biological therapy possibilities for treating osteoporosis in men
Antibodies Target Advantages Disadvantages References
Denosumab RANKL  Bone resorption Reduces immunity, skin rashes,  
high cholesterol
14,94,105,106
Odanacatib Cathepsin K  Bone resorption markers,  
 BMD spine and hip
Not known 94,107,108
Inhibitors
AMG 785 Sclerostin  Bone formation markers, BMD Oncogenic, calcium homeostasis,  
uncontrolled bone formation  
leading to complications
105,109–112
Specific to DKK1 DKK1  Bone formation
Specific to Frp Frp May  bone loss
Lithium GSK-3  BMD
603281-31-8 GSK-3  Bone formation markers, bone strength
6-bromoindirubin-3′-oxime GSK-3  Glucocorticoid-induced bone loss
AR28 GSK-3  Bone mass
Abbreviations: BMD, bone mineral density; DKK1, Dickkopf 1; Frp, frizzled-related proteins; RANKL, receptor activated nuclear factor kappa B ligand; , increase; , decrease; 
GSK-3, glycogen synthase kinase 3.





Drug Design, Development and Therapy 2013:7
also been targeted. Odanacatib, an inhibitor of cathepsin K, 
decreased bone resorption markers and increased BMD at 
the spine and hip over two years.94,107 This therapy is recom-
mended in men because it increases BMD and decreases 
the fracture rate in patients with prostate cancer, delays the 
time to the first skeletal-related event, and increases bone 
metastasis-free survival.108
The wingless-type and integrase 1 (Wnt) signaling path-
way regulates osteoblastogenesis, and inhibitors of some of 
these proteins can be considered as potential drug targets.109 
When sclerostin (a natural antagonist of the Wnt signaling 
pathway) is inhibited, the anabolic properties of bone are 
increased in animal models.110 In healthy men, inhibition 
of sclerostin using AMG 785 significantly increased bone 
formation markers and BMD, while significantly decreas-
ing bone resorption markers.111 A polymorphism of the 
gene coding for sclerostin showed site-specific association 
with BMD of the femoral neck.105 Dickkopf 1, another 
endogenous inhibitor of the Wnt signaling pathway, has 
also been investigated, and a Dickkopf 1 antagonist was 
found to increase bone formation.109 Another possible target 
is the frizzled-related proteins, which are also inhibitors of 
the Wnt signaling pathway. Studies in mice have shown that 
overexpression of serum frizzled-related proteins decreases 
bone mass and inhibits osteoblast function as well as the 
anabolic effects of parathyroid hormone.109,112 Other possible 
targets that have been reported include glycogen synthase 
kinase 3 (GSK-3), another endogenous inhibitor of the Wnt 
signaling pathway.109 Further, several inhibitors of GSK-3, 
including lithium, 603281-31-8, 6-bromoindirubin-3′-oxime, 
and AR28, have been tested.109 However, a major concern in 
using Wnt signaling pathway antagonists is the oncogenic 
effects resulting from inhibition of this pathway.109 Targeting 
specific proteins in the metabolic pathway related to bone 
metabolism is a novel approach, but extreme caution is 
needed because many of these proteins are not just part of 
bone metabolism but also play a key role in other important 
pathways.  Therefore, when these drugs are used, a balanced 
approach that increases the benefits but decreases other 
health complications and side effects must be taken into 
consideration. This approach is very important in treating 
osteoporosis, mainly because a majority of the patients are 
elderly, moreover, with increase in life expectancy the quality 
of life should also be improved.
Nutritional supplementation
Several nutritional supplements are also implicated in 
maintaining bone health. These include minerals like 
Table 3 Possible nutritional supplements for the prevention and 
treatment of osteoporosis in men
Supplements Evidence References








 n-3 fatty acids Preclinical 121,122,125










 Black cohosh 116,129
 Fructus linguistri lucidi Preclinical
 Cissus quadrangularis Preclinical




 calcium, vitamins, fatty acids, and herbal products (Table 3). 
Nutritional supplementation with calcium and vitamin D 
to increase calcium absorption is commonly prescribed to 
patients with osteoporosis, including men.4,97,113–117 Calcium 
and vitamin D monotherapy has been reported to reduce hip 
fractures.14,80,118,119 It is reported that community-dwelling 
elders are likely to have sufficient intake of calcium and 
vitamin D, but institutionalized elders showed calcium and 
vitamin D deficiency. Intermittent monofluorophosphate 
and calcium increased bone density and decreased the risk 
of vertebral fractures in upper middle aged men (mean 
age 53).120 Irrespective of ethnic background, vitamin D 
supplementation is recommended.16 Supplementation with 
calcium and vitamin D, in addition to helping bone, decreases 
hyperthyroidism and improves muscle strength, function, 
and balance.56–58
Other nutritional supplements that have shown promise 
in reducing bone loss are n-3 fatty acids, conjugated linoleic 
acid, soy isoflavones, and some herbal compounds. Several 
studies of n-3 fatty acids have reported benefits on bones 
in male animal models by decreasing prostaglandin 2121,122 
and bone resorption as well as increasing BMD at the 
lumbar vertebrae123 and tibia.124 n-3 fatty acids benefit bone 
mainly by reducing bone turnover.125 In men, a positive 
correlation has been found between consumption of doco-
sahexaenoic acid and peak BMD.126 Another fatty acid, 
known as conjugated linoleic acid and commonly found 
in milk and dairy products, increased bone mass in male 
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mice.127 Phytoestrogens like soy isoflavones increased bone 
mass in orchidectomized rats, primarily by increasing bone 
turnover markers and the microarchitecture of trabecular 
bone.128 Ipriflavone, a synthetic isoflavone, is also beneficial 
in maintaining bone mass.116
Herbal supplements and alternative medicines, including 
vitamin E, black cohosh, red clover, Fructus linguistri lucidi, 
Cissus quadrangularis, and prunes, have shown to have bone-
protective properties in preclinical studies.116,129–131 Although 
many of these studies have been conducted in females, there 
is a high probability that these will also be beneficial to men. 
More systematic studies using these promising compounds 
may be worth pursuing to develop safer and more cost-
effective treatment options.
Apart from drug interventions, nonpharmacologic thera-
pies (Table 4) including exercise and muscle-strengthening 
strategies are also recommended, eg, increasing physical 
activity in patients with osteoporosis.80 Fall prevention 
measures such as checking vision and hearing, neurologic 
assessment, and installing safety features in the home 
should be part of the treatment regimen.132,133 In addition, 
leading a healthy lifestyle, including eating healthy foods, 
avoiding tobacco, and limiting alcohol consumption is also 
recommended.133
Conclusion
Traditionally, osteoporosis was considered a disease that 
affects only women. However, a little over two decades ago, 
osteoporosis came to be recognized as a disease that is also 
prevalent in elderly men and with bleak survival outcomes 
following fracture. As the population is moving toward an 
increased life span, it is logical to predict that the number 
of patients with osteoporosis will increase. In  individuals 
suffering from osteoporosis, living conditions are highly 
compromised, apart from the financial burden on society.
Although we have learned a lot about osteoporosis 
from studies in women, there are basic differences between 
women and men which need to be addressed, hence a need 
for more studies in men. In particular, assessment must 
include standards determined for men followed by treatment 
options. Evidence from existing studies shows most men do 
not get treated for osteoporosis after a hip fracture. Patients 
should be screened during initial evaluation for serum cal-
cium, phosphorus, creatine, alkaline phosphatase, vitamin 
D, liver transaminases, thyroid-stimulating hormone, total 
testosterone, 25-hydroxyvitamin D, parathyroid hormone, 
prostate-specific antigen, bone turnover markers (ie, ter-
minal telopeptide and procollagen type 1 amino-terminal 
propeptide), glucocorticoid use, and family history in order 
to decide on the correct treatment options.4,88,106 Currently 
there are very few clinical studies on osteoporosis in men, 
limiting the understanding and development of the disease 
as well as the therapeutic options.134 Dual X-ray absorptiom-
etry, high resolution quantitated computed tomography with 
finite element analysis, and magnetic resonance imaging are 
common methods for detection of the disease.62,94 Use of 
these diagnostic tools in men after a certain age will help in 
identifying those at risk so that preventive measures to avoid 
fractures can be implemented. Moreover, the focus in iden-
tifying new drugs for preventing and treating osteoporosis 
should also include reducing or eliminating harmful side 
effects and be more cost-effective.
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